RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
BACKGROUND
Omalizumab is a humanized monoclonal anti-IgE antibody developed for the treatment of IgE-mediated diseases, including asthma. The aim of the study was to determine the effect of omalizumab treatment on changes in RANTES in exhaled breath condensate and other inflammatory markers in patients with persistent severe asthma.


METHODS
The study was conducted on a group of 19 patients with severe persistent allergic asthma treated with conventional therapy (according to GINA 2006) and with or without omalizumab (9 vs. 10 patients). Changes in inflammatory parameters [RANTES in exhaled breath condensate, exhaled nitric oxide, blood eosinophil count and serum eosinophil cationic protein (ECP)] were measured before and after 16 weeks of therapy.


RESULTS
Omalizumab-treated patients showed a statistically significant decrease in the concentrations of RANTES in exhaled breath condensate, exhaled nitric oxide (F(ENO)), serum ECP, and blood eosinophil count compared with patients with conventional therapy after 16 weeks of treatment. In this group of patients, statistically significant correlations were revealed between the decrease in RANTES and a decrease in F(ENO) and between the decrease in F(ENO) and a decrease in ECP or blood eosinophil count after omalizumab therapy.


CONCLUSIONS
Our results confirmed that during anti-immunoglobulin E therapy with omalizumab in patients with severe persistent allergic asthma, RANTES expression is decreased. This process in turn could lead to a limitation of airway inflammation and could be essential for the beneficial effect of anti-IgE therapy with omalizumab.
Zietkowski
Ziemowit
Z
Department of Allergology and Internal Medicine, Medical University of Bialystok, Sklodowska-Curie Street 24A, Bialystok, Poland. z.zietkowski@wp.pl
Skiepko
Roman
R
Tomasiak-Lozowska
Maria M
MM
Lenczewska
Danuta
D
Bodzenta-Lukaszyk
Anna
A
D000328:Adult; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000188:drug therapy*; D001944:Breath Tests; D018946:Chemokine CCL5 / Q000032:analysis / Q000378:metabolism*; D047150:Eosinophil Cationic Protein / Q000097:blood; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000032:analysis; D000069444:Omalizumab; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018946:Chemokine CCL5; C026408:anti-IgE antibodies; D000069444:Omalizumab; D009569:Nitric Oxide; D007073:Immunoglobulin E; D047150:Eosinophil Cationic Protein